ZHONGZE Therapeutics is a clinical-stage biotech company focusing on the research, development and commercialization of innovative agents for schizophrenia.

Our most advanced therapeutic compound, ZZ6398, is a multi-target small molecule. It is simultaneously effective for the three major symptoms of Schizophrenia (positive symptoms, negative symptoms, and cognitive impairment), and has the potential to become a first in class (FIC) drug. Top line results from a SAD study indicate that ZZ6398 is safe and well tolerated in healthy volunteers. ZZ6398 is currently in Phase Ib clinical study and the proof of concept (POC) study will begin by the end of 2023.  

In addition, the company has carried out a multi-target, multi-mechanism pipeline focusing on the unmet clinical needs of schizophrenia.